Myocardial Staining (TMPG 1)  Post-Stent in AMI

Slides:



Advertisements
Similar presentations
Protection Devices in PCI-Treatment of Myocardial Infarction for Salvage of Endangered Myocardium Study Presented at American College of Cardiology Scientific.
Advertisements

Unstable Angina: Embolism Can Occur Prior to PCI Thrombus in proximal RCA Stain of muscle before injection begins: TIMI Myocardial perfusion grade 1 CM.
Post-conditioning the human heart to reduce infarct size
ISCHAEMIC HEART DISEASE Acute Coronary Syndromes JD Marx Department of Cardiology University of the Free State.
Intracoronary Serotonin and Endothelin Release After PCI / Stenting Taylor AJ. Am Heart J Aug;148(2): e10 Leosco et al, AJC 1999;84:
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
Pathophysiology of Combination Therapy in AMI *Gibson et al. J Am Coll Cardiol. 1995;25: Gibson et al. Circulation. 2001;103: Combination.
Call for CASES Leszek D. Stachaczyk, MD Pawel Buszman, MD, FESC, FSCAI American Heart of Poland, Ustroñ, Poland & CCU, Upper-Silesian Center of Cardiology,
Results of CRYSTAL AMI: A Pilot Trial Before INFUSE AMI, the Concept and Evolution in Thrombus Management Saihari Sadanandan, MD, FACC, FASE, Dip. CBNC,
GP IIb/IIIa Inhibition in STEMI: Growing Clinical Trial Evidence.
Intravenous GP IIb/IIIa Inhibitors Abciximab (c7E3 Fab, ReoPro) = Human- murine chimeric monoclonal Fab antibody fragment Eptifibatide (Integrilin) =
Clinical Trial Results. org C. Michael Gibson, M.S., M.D. Director TIMI Data Coordinating Center Invasive Cardiologist Beth Israel Deaconess Medical Center.
Intracoronary Eptifibatide Bolus Administration During Percutaneous Coronary Revascularization for Acute Coronary Syndromes With Evaluation of Platelet.
Is PCI necessary for AMI related artery with TIMI 3 flow ? Donghoon Choi Yonsei Cardiovascular Center Yonsei University College of Medicine.
Primary Angioplasty and Hemodynamic Support in Cardiogenic Shock Department of Internal Medicine, College of Medicine, Yonsei University Hyuck Moon Kwon,
Effect of Intracoronary Streptokinase Administered Immediately after Primary PCI on Left Ventricular Infarct Size, Volume and Function (J Am Coll Cardiol.
Improving outcome of STEMI PCI: Preliminary Results of Crystal AMI trial Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators.
Beyond TIMI 3 Flow CTFC < 14 CTFC > % (n=41) (n = 18/640) (n =35/563) 2.8% p= “TIMI 4” Flow TIMI 3 Flow 14 < CTFC < % % Risk of In Hospital.
The “Code White” Team of Dr. William Ganz: 1979 Goal of IC SK Before PCI: Get the artery open.
The 90 Minute Wall: 60% Rates of TIMI Grade 3 Flow % TIMI 3 Flow.
Proof of Concept #1: Occluded Arteries Cause Acute MI Proof of Concept #1: Occluded Arteries Cause Acute MI Proof of Concept #2: Drugs (in this case IC.
Could an antianginal metabolic agent have an impact on prognosis in ischemic patients? Beneficial effects of trimetazidine in patients with acute myocardial.
Direct Stenting is Better (Debate Session) 동아의대 김 무 현.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
New strategies and perfusion/aspiration devices for primary PCI Sandra Garcia Cruset, PhD. Cordynamic B.U. Marketing Manager.
Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.
PROTECT: What Have We Learned Lesson 2: TMPG is associated with clinical and biomarker outcomes following PCI.
Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet and Anti-Thrombotic.
Randomized Early versus Late AbciXimab in Acute Myocardial Infarction treated with primary coronary intervention (RELAx-AMI Trial) Mauro Maioli M.D., Francesco.
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Recovery of Myocardial Perfusion in Acute Myocardial.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.
From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:
M-Guard stent in STEMI patients with high thrombus burden lesions Mahmoud Shabestari Baktash Bayani Ali Eshraghi Bahram Shahri Mashhad University.
CRT 2015 Unmet Needs in STEMI Interventions
The American College of Cardiology Presented by Dr. Adnan Kastrati
Intra Coronary AdjunctivE Tenecteplase During Primary PCI for STEMI:
Impella 2.5® Device Is Associated with Improved Survival in AMICS
No Reflow Reflow P value Arrhythmia 40% 18% Lecture Notes
ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
Section 5: Intervention and drug therapy
Clopidogrel Reduces ADP-Induced Expression of Platelet-derived CD40L
3-Year Clinical Outcomes From the RESOLUTE US Study
PROTECT – TIMI 30 Trial Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet.
Randomized Comparison in the Setting of Acute MI
In STEMI Complete Reperfusion (TFG 3, TMPG 3, ST Res  70%) is Associated with a Greater Percent of Receptors Occupied by Integrilin 52.0% % Pts With Complete.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
52.0% Complete Resolution TFG 3 TMPG 3 ST Resolution  70% p=0.006
Secondary Efficacy Endpoints
TIMI Myocardial Perfusion (TMP) Grades Dye strongly persistent
Role of Stenting in Acute MI: PAMI Stent Pilot Trial
Dye strongly persistent
Mechanical Prevention of Distal Embolization During Primary Angioplasty: Safety, Feasibility, and Impact on Myocardial Reperfusion Ugo Limbruno, MD, PhD;
Maintenance of Long-Term Clinical Benefit with
A New Angiographic Risk Score in Facilitated PCI
Dye strongly persistent
Association of Troponin Elevation with Risk of Mortality in Acute Coronary Syndromes Mortality at 42 Days  % A study by Antman and.
European Heart Journal Advance Access
MRI Hyperenhancement is Associated with Myonecrosis Following PCI
Evolution of Myocardial Blush after MI
GUSTO 1 Trial 41,000 patients enrolled, landmark study
ESPRIT INTEGRITI TACTICS Rate of Increase in DSA
FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.
Cardiovascular Epidemiology and Epidemiological Modelling
Dye strongly persistent
Presentation transcript:

Myocardial Staining (TMPG 1)  Post-Stent in AMI 28.6% % TMPG 1 13.5% n = 118 n = 118 CM Gibson, J Thrombolysis & Thrombosis, 2002 in press

Intracoronary Devices and Embolic Potential Lecture Notes The left panel shows the results of nuclear scanning performed during rotablation. This demonstrates that rotablation is associated with the development of new perfusion defects during the procedure, most likely due to distal embolization. Abciximab therapy reduced the incidence of perfusion defects as shown in the upper panel. Two new embolization protection devices are shown in the right panel that may reduce the incidence of distal embolization during PCI. (Topol, 1999; Topol, 2000) Topol, E. Circulation. 2000;101:570-580.

Intracoronary Serotonin Release After Stenting Stenting causes greater serotonin release than PTCA Stenting may cause greater arterial damage, greater plt. deposition, and greater plt. activation leading to vasoconstriction Leosco et al, AJC 1999;84:1317-1322

Impact of IC Adenosine & GP 2b3a Inhibitor on TIMI Myocardial Perfusion Grade Post PTCA Post PTCA + Adenosine Distal LAD with TIMI 3 Grade Blush Distal LAD with no blush (DSA = 0.1 Gray) (DSA = 5.2 Gray) CM Gibson 2000

% Death, MI, CHF, Recurrent Angina Impact of IC Adenosine on Clinical & Electrocardiographic Outcomes in the Setting Primary PTCA N=27 Placebo N=27 Adenosine 4 mg in 2 ml via central lumen of PTCA balloon p < 0.02 p < 0.03 p < 0.04 % of Patients % Death, MI, CHF, Recurrent Angina % Developing Q Waves Marzilli et al, Circulation 2000; 101:2154-2159

Hypothermia in MI Reduces Infarct Size No Cooling Cooling

Non-culprit CTFCs Improve Following PCI of the Culprit Artery 10.4 + 16.0 Dilating the culprit stenosis speeds up flow in the uninvolved artery (non-culprit artery) in acute coronary syndromes P < 0.0001 CTFC Improvement in Non-Culprit N = 134 N = 228 - 0.7 + 8.6 Gibson CM et al, Am J Cardiol 2000

Alpha Adrenergic Blockade Improves Recovery of Myocardial Perfusion After Stenting in AMI Gregorini et al, Circulation 1999; 99: 482-490

Alpha Adrenergic Blockade Improves Recovery of Myocardial Perfusion After Stenting in AMI Gregorini et al, Circulation 1999; 99: 482-490

Downstream Targets Large embolii: Filters Small embolii (thrombii): Filters & GP 2b3a inhibitors Vasoconstrictor release: GP 2b3a inhibitors Spasm: Adenosine, Ca channel blockers, alpha blockers, avoid over sizing with PCI, high pressure inflations, serotonin inhibitors, endothelin inhibitors Endothelial & Myocardial swelling: Ca channel blockers, hypothermia, DHEA, Na / H pump inhibitors, anti-inflammatory approaches